CAMBRIDGE, Mass.–(BUSINESS WIRE)– #ClinicalResearch–Skylark Bio, a clinical-stage biotechnology company developing precision genetic medicines for hearing loss and other monogenic disorders, has received a unanimous recommendation from the independent Data Safety Monitoring Board (DSMB) to advance the SONIX Phase 1/2 clinical trial of SKY-GJB2, the Companyās investigational inner-ear-targeted gene therapy for GJB2-mediated hearing loss. After reviewing the safety data from the four pediatric participants aged 2
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks

